Biologics in the treatment of uveitis
FR Imrie, AD Dick - Current opinion in ophthalmology, 2007 - journals.lww.com
FR Imrie, AD Dick
Current opinion in ophthalmology, 2007•journals.lww.comBiologic therapies have increased the treatment options for sight-threatening uveitis. Despite
experimental rationale, the lack of evidence from randomized controlled studies limits our
understanding of when to commence therapy, which agent to choose and how long to
continue treatment. Additionally, the high cost and potential side effects of all biologic agents
have limited their current use to uveitis refractory to immunosuppression.
experimental rationale, the lack of evidence from randomized controlled studies limits our
understanding of when to commence therapy, which agent to choose and how long to
continue treatment. Additionally, the high cost and potential side effects of all biologic agents
have limited their current use to uveitis refractory to immunosuppression.
Summary
Biologic therapies have increased the treatment options for sight-threatening uveitis. Despite experimental rationale, the lack of evidence from randomized controlled studies limits our understanding of when to commence therapy, which agent to choose and how long to continue treatment. Additionally, the high cost and potential side effects of all biologic agents have limited their current use to uveitis refractory to immunosuppression.
Lippincott Williams & Wilkins